Gastric retention will provide advantages such as delivery of drugs with narrow absorption windows in the small intestinal region, namely proximal parts of the gastrointestinal tract (stomach and/or duodenum). Pharmaceutical dosage forms which remain in stomach for a prolonged period of time after oral administration and release the active ingredient in a controlled manner are important for the delivery of a wide variety of drugs (1-5).
ments (9) . MS is highly soluble throughout physiological pH. Drug solubility was 157 mg mL -1 in water (pH = 5.5) and 183 mg mL -1 in 0.1 mol L -1 HCl solution (pH = 1.0). It is therefore a suitable candidate with high solubility for a monolithic system (10) .
The present study involves the design and optimization of a novel gastroretentive, floating, swellable, controlled release tablet by combining three polymers with different concentrations: sodium alginate (SA) -rapidly hydrating, rate controlling polymer, sodium carboxymethylcellulose (NaCMC) -gel forming agent, and magnesium alumino metasilicate (MAS) -swelling controlling agent. Furthermore, calcium sulphate dihydrate (CS) -cross linker, gel strength enhancer for SA, and sodium bicarbonate (SBC) as a gas generating agent were also used. The combined effect of these polymers on the floating behaviour and on in vitro release pattern of the MS has also been evaluated.
EXPERIMENTAL

Materials
Metoprolol succinate was received as a gift sample from Alembic Ltd., India. SA was purchased from Anshul Agencies and NaCMC from Auqualon, India. CS was purchased from JRS Pharma and SBC from S.D. Fine-Chem Ltd., India. MAS was purchased from Gangwal Chemicals, India. All the other chemicals used were of analytical grade.
Methods
Calibration curves of MS were determined in 0.1 mol L -1 HCl and in methanol at l = 222 nm (R = 0.9932 and 0.9982, respectively), using a UV-Visible spectrophotometer (Lambda 25, Perkin-Elmer, USA). The calibration curve in 0.1 mol L -1 HCl was used for dissolution studies while drug content was determined using the calibration curve in methanol.
Preparation of MSGR tablets
MSGR tablets were prepared according to the composition of optimized batches (Table I) . MSGR tablets (200 mg) were prepared by the direct compression method. Initially, all ingredients were sieved through 425-mm sieve opening, weighed and mixed for 10 min in a planetary mixer (Kenwood PM 900, UK) at 10 rpm. The drug was mixed with SA, NaCMC, MAS, SBC and CS. Finally, the MAS was added as a lubricant and mixed for additional 2-3 min. Tablets were compressed on a tabletting machine (Minipress by Clit, 10 stations, Chamunda Pharma Machinary Pvt. Ltd., India) fitted with a 10.4-mm circular shaped standard concave punch with tableting force of (3.5 ± 0.5)´10 3 kg.
Characterization of MSGR tablets
The prepared MSGR tablets were tested for physical characteristics, viz., mass variation, thickness (measured using a Vernier caliperse, Mitutoyo Corporation, Japan), hardness (measured with a hardness tester, Erweka, Germany) and friability (determined using a Roche friabilator, Germany).
Drug content
Accurately weighed MSGR tablets (10 tablets) were crushed to form a fine powder. An accurately weighed quantity equivalent to 200 mg of MS was transferred to a 100-mL volumetric flask. To this, 50 mL methanol was added and sonicated for 15 min. Volume was made up to the mark with methanol. The solution was filtered through a 0.45-mm filter and 1 mL of this solution was diluted to 50 mL with methanol. Absorbance was measured at 222 nm.
In vitro dissolution studies
The release rate of MSGR tablets (n = 3) was determined with a USP dissolution apparatus-II (paddle method) using 75 rpm speed and 900 mL of 0.1 mol L -1 HCl as dissolution medium at 37 ± 0.5°C (11) . A sample (10 mL of the solution) was withdrawn from the dissolution apparatus (Electrolab, India) at regular time intervals up to 24 h (1, 2, 4, 6, 8, 10, 12, 16, 20 and 24 h) and replaced with the same volume of fresh dissolution medium. The samples were filtered through a 0.45-mm membrane filter and diluted to a suitable concentration with 0.1 mol L -1 HCl, and the absorbance of these solutions was measured at 222 nm. Cumulative percentage of drug release was calculated using the equation obtained from a standard curve. 
In vitro buoyancy studies
The in vitro buoyancy studies were performed by measuring the floating lag times according to the method of Rosa et al. (12) . The tablets were placed in a 100-mL beaker containing 0.1 mol L -1 HCl. The time required for the tablet to rise to the surface and float was defined as the floating lag time (Flag).
Box-Behnken design
Statistical analysis of the Box-Behnken design batches was performed by multiple linear regression analysis using SYSTAT 12. A Box-Behnken design was constructed to study the effect of the independent variables, viz., the amount of SA (X 1 ), the amount of NaCMC (X 2 ) and the amount of MAS (X 3 ) on dependent variables like t 25 , t 50 , t 75, Flag of MSGR tablets.
RESULTS AND DISCUSSION
Physical characterization of the tablets
Tablet mass of all the formulations was found to be 600.0 ± 20.0 mg. Tablet thickness was found to be 6.0 ± 0.1 mm. The hardness of the formulation was 70 to 90 N, indicating satisfactory mechanical strength. Percentage mass loss in the friability test was 0.2 to 0.5 % in all cases, which was an indication of good mechanical resistance of the tablet. Tablets of all the prepared batches containing MS were found to be within 100.0 ± 5.0 % of the labelled content, indicating content uniformity of the prepared formulations.
In vitro dissolution studies
Batch MS01 released 75 % of MS in 16 h with Flag of 48 s compared to batch MS13 which showed 75 % MS release in 16 h and the Flag of 540 s, and batch MS02 with a Flag of 45 s and t 75 of 10.2 h. Based on this data, batch MS01 was considered the best formulation with desirable Flag, therefore this formulation was selected for factorial studies to optimize the formulation and to study the effects of variables on the formulation (Tables  II and III) . Prepared batches show variation in drug release due to different concentrations of polymers used during their preparation (Fig. 1) .
In vitro buoyancy studies
The results of in vitro buoyancy studies showed quick floating of the tablet within 2 min after placing the tablet in dissolution medium. Studies showed that no single polymer individually was sufficient to produce buoyancy and integrity of the tablet. Flag varied between 45 s to 15 min (Table II) . Buoyancy mainly depended upon the quantity of MAS and SBC. SBC of 5 % was found optimal with optimum integrity and controlled release profile of the drug from the tablet. MAS produces swelling of the tablet while SBC has the ability to generate gas in the presence of hydrochloric acid, which gets entrapped in the tablet. This leads to reduction in the density of the tablet, thereby producing floating.
In case of batches MS01 and MS02, the MAS quantity of 5.0 % produced Flag of 48 s and 45 s, respectively, while in batch MS13, the quantity of MAS of 10.0 % produced Flag of 540 s. The combination of polymer SA and NaCMC with CS showed integrity of the system and produced buoyancy in a minimum of time. These hydrophilic polymers hydrate and swell rapidly due to the imbibing of the gastrointestinal fluid by the tablet, density of the tablet is lowered due to swelling and gas formation which helps in system buoyancy. 
Effect of the release modulating agent and swelling morphology
Effect of 5-10 % of MAS that increased the Flag and controlled the release profile was studied. This was due to its extremely fine, porous nature, which allows the medium to penetrate into the tablet through the small holes in its particles, leading to reduction in tablet density and producing swelling that increases the Flag. Medium uptake by the tablet was determined in 0.1 mol L -1 HCl. MSGR tablet showed rapid hydration and gelling intact up to 12 h.
Kinetics of drug release
Sigma Plot 10 was used for controlled release curve fitting to select the most appropriate model. The dissolution data for batch MS01 was fitted to the Bekker-Lonsdale, first-order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas models (13-15). The release profile of the optimized batch MS01 fitted best to the first-order (R 2 = 0.9868 and n = 0.543), indicating non-Fickian diffusion or anomalous transport, with release by diffusion and swelling (combination of diffusion and erosion-controlled release). Nevertheless, the Korsmeyer-Peppas model has also shown a good coefficient of determination (Table IV) .
Box-Behnken design
The dependent variables chosen were the times required for 25, 50 and 75 % the cumulative drug release and Flag; the results showed a wide variation (Table II) . The data clearly indicate that the values of t 25 , t 50 , t 75 and Flag are strongly dependent on the in- 
The values obtained for the coefficient of determination indicate a good fit. The data demonstrate that both X 1 and X 2 affect the drug release (t 25 , t 50 and t 75 ). It may also be concluded that the low level of X 1 (amount of SA) and higher level of X 2 (amount of NaCMC) favour preparation of gastroretentive-sustained release MS tablets. High values of the X 1 X 2 coefficient also suggest that the interaction between X 1 and X 2 had a significant (p < 0.05) effect on t 25 , t 50 and t 75 . It can be concluded that the drug release pattern may be changed by appropriate selection of the X 1 , X 2 and X 3 levels. The results in Table II reveal that batches MS02, MS08, MS09 and MS12 were close to the required attributes of gastroretentive tablets in terms of t 50 , t 75 and Flag, while batch MS01 was ideal because of its controlled release profile for 16 h (960 min) with the desirable Flag of 48 s. This was, therefore, considered the best formulation among all the prepared formulations.
The fitted equations relating to the response at t 25 , t 50 , t 75 and Flag are shown in equations (5-8) 
Values of the coefficients of determination indicate a good fit. As seen from the above equations, the individual factors, i.e., the amount of SA (X 1 ) and the amount of NaCMC (X 2 ) had a negative effect on t 25 , t 50 , and t 75 but in combination (X 1 X 2 ) showed a significant (p < 0.05) positive effect. In case of Flag, X 1 showed a negative effect (decreasing floating lag time) whereas X 2 had a positive effect (increasing floating lag time) while in combination they showed a negative effect (Fig. 2) .
The following equations (9) (10) (11) (12) Individual factors X 1 and X 3 showed a negative effect on t 25 , t 50 , t 75 but their combination showed a significant (p < 0.05) positive effect. Flag X 1 showed a positive effect but X 3 had a negative effect.
The following equations (13) (14) (15) (16) 
The above equations indicate that individual factors X 2 and X 3 show a significant (p < 0.05) positive effect on t 25 , t 50 , t 75 and Flag but their combination had a negative effect.
It followed from the systematic study, using the Box-Behnken design, that the amounts of SA, NaCMC and MAS had a significant effect (p < 0.05) on t 25 , t 50 , t 75 and Flag. Thus, by selecting a suitable concentration of the rapidly hydrating-rate-controlling polymer (SA), gel forming agent (NaCMC) and swelling-controlling agent (MAS), the desired dissolution profile can be achieved.
CONCLUSIONS
The present study involved the design of a novel gastroretentive floating and swellable, controlled-release, tablet of MS. Its comprised the release-rate-controlling hydrophilic polymers, a release modulator and a gas generating agent. Upon administration, the MSGR tablet was hydrated and swelled rapidly due to imbibition of the gastrointestinal fluid; subsequent gas generation helped the system buoyancy and the desired release profile. Optimized batch formulation MS01 showed buoyancy with Flag time less than one min (48 s) and remained floating for 16 h. Minimum floating time and higher percetange of swelling of the MS01 formulation is required to increase its residence time in the stomach and eventually improve the extent of bioavailability. The present study confirmed the test of the suitability of gastroretentive platform technology developed for the MSGR tablet without changing any excipients and process parameters. The optimized batch MS01GR tablet, prepared using novel combinations of SA, NaCMC and MAS, can be successfully employed as a once-a-day oral controlled release drug delivery system.
